Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Commentary on “DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.”
Platinum-based chemotherapy remains the standard treatment for advanced urothelial carcinoma by inducing DNA damage. We hypothesize that somatic alterations in DNA damage response and repair (DDR) genes are associated with improved sensitivity to platinum-based chemotherapy. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 30, 2018 Category: Urology & Nephrology Authors: MY Teo, RM Bambury, EC Zabor, E Jordan, H Al-Ahmadie, ME Boyd, N Bouvier, SA Mullane, EK Cha, N Roper, I Ostrovnaya, DM Hyman, BH Bochner, ME Arcila, DB Solit, MF Berger, DF Bajorin, J Bellmunt, G Iyer, JE. Rosenberg Tags: Urologic Oncology Survey Source Type: research

Commentary on “A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy—A single-institution experience.”
Management of high-grade T1 (formerly T1G3) bladder cancer continues to be controversial. Should patients with T1G3 bladder cancer have an immediate radical cystectomy or should they receive intravesical bacillus Calmette-Gu érin preserving bladder? Gemcitabine and cisplatin (GC) adjuvant chemotherapy may help to strike a balance between intravesical and early cystectomy. For purposes of this study, we continue to refer high-grade T1 lesion as “T1G3.” (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 30, 2018 Category: Urology & Nephrology Authors: GL Yang, LH Zhang, Q Liu, ZL Wang, XH Duan, YR Huang, JJ. Bo Tags: Urologic Oncology Survey Source Type: research

The loss of BAP1 protein expression predicts poor prognosis in patients with nonmetastatic clear cell renal cell carcinoma with inferior vena cava tumor thrombosis
Renal cell carcinoma (RCC) is characterized by a propensity for extension into the renal vein and inferior vena cava (IVC) and is associated with poor prognosis. BAP1 mutation, which occurs in about 15% of patients with clear cell RCC (ccRCC), also predicts poor prognosis. The aim of this study was to elucidate the association between BAP1 protein expression and clinicopathological outcomes in patients with nonmetastatic ccRCC with an IVC tumor thrombus (IVCTT). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 28, 2018 Category: Urology & Nephrology Authors: Suguru Oka, Naoko Inoshita, Yuji Miura, Ryosuke Oki, Yu Miyama, Shoichi Nagamoto, Kohei Ogawa, Kazushige Sakaguchi, Chihiro Kondoh, Kazuhiro Kurosawa, Shinji Urakami, Toshimi Takano, Toshikazu Okaneya Tags: Original article Source Type: research

The natural history of large renal masses followed on observation
The safety and feasibility of active surveillance in comorbid patients with renal masses ≥4.0cm is uncertain. The aim of this study is to describe our institutional experience with the observation of large renal masses. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 28, 2018 Category: Urology & Nephrology Authors: Karim Marzouk, Amy Tin, Nick Liu, Daniel Sjoberg, Abraham Ari Hakimi, Paul Russo, Jonathan Coleman Tags: Original article Source Type: research

Is imperative partial nephrectomy feasible for kidney cancer with venous thrombus involvement? Outcomes of 42 cases and matched pair analysis with a large radical nephrectomy cohort
Radical nephrectomy (RN) with/without ( ±) thrombus excision (ThE) is the undisputed standard treatment for kidney cancer (KC) with renal or caval thrombus (Th). However, partial nephrectomy (PN) ± ThE may be considered in rare cases due to imperative (I) indications. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 22, 2018 Category: Urology & Nephrology Authors: Giancarlo Marra, Paolo Gontero, Michele Brattoli, Claudia Filippini, Umberto Capitanio, Francesco Montorsi, Siamak Daneshmand, William C. Huang, Estefan ía Linares Espinós, Juan I. Martínez-Salamanca, James M. McKiernan, Richard Zigeuner, John A. Liber Tags: Original article Source Type: research

A contemporary population-based analysis of the incidence, cost, and outcomes of postoperative delirium following major urologic cancer surgeries
Postoperative delirium (PD) is associated with poor outcomes and increased health care costs. The incidence, outcomes, and cost of delirium for major urologic cancer surgeries have not been previously characterized in a population-based analysis. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 22, 2018 Category: Urology & Nephrology Authors: Albert Ha, Ross E. Krasnow, Matthew Mossanen, Ramzy Nagle, Tammy T. Hshieh, James L. Rudolph, Steven L. Chang Tags: Original article Source Type: research

Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell carcinoma
To assess the associations between perioperative allogeneic blood transfusions (ABTs) and recurrence, overall and renal cell carcinoma (RCC)-specific survival in patients undergoing surgical treatment for clinically localized disease. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 21, 2018 Category: Urology & Nephrology Authors: Matvey Tsivian, Michael R. Abern, Efrat Tsivian, Christina Sze, Ghalib Jibara, Edward N. Rampersaud, Thomas J. Polascik Tags: Original article Source Type: research

Effect of blood transfusions on oncological outcomes of surgically treated localized renal cell csarcinoma
To assess the associations between perioperative allogeneic blood transfusions (ABTs) and recurrence, overall and renal cell carcinoma (RCC)-specific survival in patients undergoing surgical treatment for clinically localized disease. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 21, 2018 Category: Urology & Nephrology Authors: Matvey Tsivian, Michael R. Abern, Efrat Tsivian, Christina Sze, Ghalib Jibara, Edward N. Rampersaud, Thomas J. Polascik Tags: Original article Source Type: research

Modifiable risk factors to reduce renal cell carcinoma incidence: Insight from the PLCO trial
Identify modifiable factors contributing to renal cell carcinoma in the PCLO to target disease prevention and reduce health care costs. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 17, 2018 Category: Urology & Nephrology Authors: Jonathan Gelfond, Osamah Al-Bayati, Aashish Kabra, Kevan Iffrig, Dharam Kaushik, Michael A. Liss Tags: Original article Source Type: research

Cover 2 - Masthead
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 16, 2018 Category: Urology & Nephrology Source Type: research

Editorial Board
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 16, 2018 Category: Urology & Nephrology Source Type: research

Table of Contents
(Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 16, 2018 Category: Urology & Nephrology Source Type: research

PLIN3 is up-regulated and correlates with poor prognosis in clear cell renal cell carcinoma
PLIN3, one of the members of the perilipin family, has been reported to be involved in the formation and accumulation of lipid droplets. However, the expression levels and diagnostic and prognostic value of PLIN3 in renal cell carcinoma (RCC) remain unclear. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 14, 2018 Category: Urology & Nephrology Authors: Keshan Wang, HaiLong Ruan, ZhengShuai Song, Qi Cao, Lin Bao, Di Liu, TianBo Xu, HaiBing Xiao, Cheng Wang, Gong Cheng, JunWei Tong, XianGui Meng, HongMei Yang, Ke Chen, XiaoPing Zhang Tags: Original article Source Type: research

Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival
Pretreated C-reactive protein (CRP) has been suggested as one of the most important prognostic factors for metastatic renal cell carcinoma (mRCC). The aim of this study was to investigate the prognostic impact of the change in CRP level before and after cytoreductive nephrectomy (CN) in patients with mRCC treated with tyrosine kinase inhibitor. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 14, 2018 Category: Urology & Nephrology Authors: Jun Teishima, Shinya Ohara, Shunsuke Shinmei, Shogo Inoue, Tetsutaro Hayashi, Hideki Mochizuki, Koji Mita, Masanobu Shigeta, Akio Matsubara Tags: Original article Source Type: research

What is the hospital volume threshold to optimize inpatient complication rate after partial nephrectomy?
To find a cutoff of hospital volume for elective partial nephrectomy (PN) for kidney cancer that can minimize the inpatient morbidity of this procedure. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - May 14, 2018 Category: Urology & Nephrology Authors: Sohrab Arora, Jacob Keeley, Daniel Pucheril, Mani Menon, Craig G. Rogers Tags: Original article Source Type: research